Glenmark's US Subsidiary Receives ANDA Approval for Two Drugs
Glenmark Pharmaceuticals Inc., USA has been granted final approval by the US FDA for its Hailey 1.5/30 (Norethindrone Acetate and Ethinyl Estradiol Tablets USP, 1.5 mg/30 mcg), the generic version of Loestrin 21 1.5/30 Tablets, of Allergan Pharmaceuticals International Ltd. and for Hailey Fe 1.5/30 (Nor ethindrone Acetate and Ethinyl Estradiol Tablets, USP and Ferrous Fumarate Tablets, 1.5 mg/30 mcg), the generic version of Loestrin Fe 1.5/30, also of Allergan. According to IQVIA, sales data for the 12-month period ending April 2018, the Loestrin 21 1.5/30 tablets market achieved annual sales of approximately $24.2-mn and the Loestrin Fe 1.5/30 market achieved annual sales of approximately $41.3-mn.
Looking for chemical products? Let suppliers reach out to you!
You May Interested In
β-Nicotinamide Adenine Dinucleotide High Quality NAD+ CAS 53-84-9 Exclusive Production Factory CAS NO.53-84-9
$75/UNIT FOB
GHKCU 50mg High Purity Peptide Not For Human Use
$78/UNIT FOB
2026-06-26
-
Life Sciences Industry Overview
The coverage spans the global life sciences industry across pharmaceuticals and food & nutrition, tracking the shift from lowest-cost sourcing to supply continuity, quality, and risk management, along with product trends and the growing edge of differentiated, globally capable players.Published in: June.2026
Trade Alert
Delivering the latest product trends and industry news straight to your inbox.
(We'll never share your email address with a third-party.)
Related News
-
Nirma acquires majority stake in Glenmark Life Sciences
-
West Asia Tensions Squeeze Pharma Raw Materials
-
U.S. Onshoring Debate Exposes API Raw-Material Gap
-
BASF Raises API and Excipient Prices
-
IPEC Updates Excipient Qualification Guidance
-
Pharmaceutical Tariffs Put Ingredients Back in Focus
-
Roche Takes Natco to Supreme Court Over Generic Risdiplam Launch in India
-
India Accuses Balaji Amines of Manufacturing Pharma-Grade Propylene Glycol Without Drug Manufacturing Licence
-
J&J to Spin Off Orthopedics Business, Raises 2025 Forecast
-
Bayer’s Ambitious Gene & Cell Therapy Pipeline Eyes Parkinson’s, Oncology, Rare Diseases
Recommend Reading
-
Aspen Secures Approval to Market Lilly’s Mounjaro for Weight Loss in South Africa
-
Bristol Myers Squibb Launches Mavacamten (“Kopozgo”) in India for Obstructive Hypertrophic Cardiomyopathy
-
The $6 Billion Gold Rush: Generic Semaglutide Set to Reshape Global Pharma After Patent Cliff
-
The Pill That Could Swallow the Needle: Novo Nordisk Launches Oral Wegovy in U.S. Weight-Loss Revolution
-
Merck to Lay Off 150 Workers at US Gardasil Plant Amid Sales Weakness
-
Multiple Factors Interwoven, Short-Term Fluctuations in Polyethylene
-
This Week, PET Bottle Chip Spot and Futures Prices Move Downward in Tandem in China
-
BASF, Covestro, Huntsman Raise MDI Prices in North America Amid Global Supply Crunch
-
UAE Withdraws from OPEC
-
Cost Support, Supply Tightening, PTA Prices Fluctuating and Rising